SL-501, a Next-Generation Targeted Therapy Directed to IL-3R, Inhibits the Growth of Tyrosine Kinase Inhibitor-Resistant CML Cells
SL-501, a next-generation targeted therapy directed to IL-3R, inhibits the growth of tyrosine kinase inhibitor-resistant CML cells. AACR 2014. Abstract | Poster
